Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6271194 | 0.89 | ALDH1A1 (0.46) | ALDH1A1CYP3A4TSHRKDM4E | |
| SCHEMBL27373535 | 0.83 | ALDH1A1 (0.38) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL20056438 | 0.83 | — | — | |
| SCHEMBL24792680 | 0.82 | ALDH1A1 (0.39) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL24872306 | 0.80 | KISS1R (0.35) | KDM4E | |
| SCHEMBL24446202 | 0.80 | KISS1R (0.35) | KDM4E | |
| SCHEMBL18923159 | 0.79 | — | — | |
| SCHEMBL10306197 | 0.79 | — | — | |
| SCHEMBL23945844 | 0.78 | ALDH1A1 (0.38) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL22268686 | 0.78 | CACNA2D1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019204781-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DESIGN THERAPEUTICS INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| EP-2594563-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | ALDH1A1 1721/4885CYP3A4 4447/4885TSHR 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.